Published in Blood Weekly, February 10th, 2000
Triclopidine, frequently administered as an antithrombotic after coronary stenting, can elicit side effects such as neutropenia or thrombocytopenia. To test the efficacy of cilostarol as an alternative to triclopidine, Y. S. Yoon and colleagues at Yonsei University, South Korea, randomly administered cilostarol with aspirin (C+A) or triclopidine with aspirin (T+A) to 300 patients, who each received 1 of the drug combinations 2 days prior to stenting.
The researchers found that 1.4% of the C+A group and 2.0% of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.